Sichuan Kelun Pharmaceutical Co., Ltd.

002422

CNE100000PW7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
32.25 ^CNY	+2.87%		+3.66%	+11.02%

Jul. 02	Kelun-Biotech to Buy Equipment from Affiliate	MT
Jul. 02	Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit	MT

Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 26, 2022.

January 03, 2023 at 11:00 am EST

From October 1, 2022 to October 24, 2022, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 7,272,164 shares, representing 0.52% for CNY 131.69 million under the buyback announced on April 26, 2022.

Latest news about Sichuan Kelun Pharmaceutical Co., Ltd.

Kelun-Biotech to Buy Equipment from Affiliate	Jul. 02	MT
Kelun-Biotech to Buy Equipment from Sichuan Kelun Pharmaceutical's Unit	Jul. 02	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024	May. 22	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug	Mar. 12	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	Jan. 22	MT
Kelun Pharmaceutical's Olaparib Tablets Get Nod from Chinese Drug Regulator	Jan. 22	MT
Kelun Pharma Gets Registration Approval in China for Immune Thrombocytopenia Drug	Jan. 17	MT
Kelun Pharma Sees Up to 50% Jump in 2023 Profit	Jan. 15	MT
Kelun Pharma's Unit Gets US FDA's Orphan Drug Designation to A400	Nov. 28	MT
Kelun Pharmaceutical's Unit Gains Registration Certificate for Ceftazidime Avibactam Sodium/Sodium Chloride Injection	Nov. 01	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Kelun Pharma Ends Cancer Drug Contract, Revises Partnership With Merck	23-10-23	MT
Global markets live: Foxconn, Roche, Eli Lilly, Chevron, Apple...	23-10-23
The good, the bad and the ugly	23-10-23
Merck discontinues some cancer drug development with China's Sichuan Kelun	23-10-23	RE
Kelun Pharma Unit Obtains Registration Approval in China for Bacterial Infection Drug	23-10-18	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug	23-08-15	MT
Kelun Pharma's Unit Gets Gadobutrol injection Certified	23-07-13	MT
Kelun Pharma Expects Up to 66% Jump in H1 Profit	23-07-05	MT
China's Sichuan Kelun-Biotech opens books for $208 million Hong Kong IPO - term sheet	23-06-28	RE
Kelun Pharma Registers GERD Drug in China	23-06-27	MT

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

More charts

Company Profile

Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.25 CNY

Average target price

42.04 CNY

Spread / Average Target

+30.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SICHUAN KELUN PHARMACEUTICAL CO., LTD.	+11.02%	7.08B
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B
PFIZER, INC.	+0.45%	164B

Other Pharmaceuticals

Sichuan Kelun Pharmaceutical Co., Ltd.

Equities

002422

CNE100000PW7

Pharmaceuticals

Tranche Update on Sichuan Kelun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 26, 2022.

EPS Revisions